In one paragraphArticle in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
13 authors.
Tian QiuDepartment of Chemical and Systems Biology, ChEM-H and Stanford Cancer Institute, Stanford Medical School, Stanford University, Stanford, CA, 94305, USA.ORCID 0000-0002-7168-0715 Yeuan Ting LeeLaura and Isaac Perlmutter Cancer Center, New York University Langone Health, New York, New York, 10016, USA.
Brendan G DwyerDepartment of Chemical and Systems Biology, ChEM-H and Stanford Cancer Institute, Stanford Medical School, Stanford University, Stanford, CA, 94305, USA.ORCID 0000-0001-8593-4184 Yi Jer TanLaura and Isaac Perlmutter Cancer Center, New York University Langone Health, New York, New York, 10016, USA.
Ting ChenLaura and Isaac Perlmutter Cancer Center, New York University Langone Health, New York, New York, 10016, USA.
Bryan A RomeroDepartment of Chemical and Systems Biology, ChEM-H and Stanford Cancer Institute, Stanford Medical School, Stanford University, Stanford, CA, 94305, USA.ORCID 0009-0006-0022-2457 Yanlan WangDepartment of Pathology, Stanford University, Stanford, CA, 94305, USA.
Jiehui DengLaura and Isaac Perlmutter Cancer Center, New York University Langone Health, New York, New York, 10016, USA.
Tinghu ZhangDepartment of Chemical and Systems Biology, ChEM-H and Stanford Cancer Institute, Stanford Medical School, Stanford University, Stanford, CA, 94305, USA.ORCID 0000-0003-1028-8020 Stephen M HinshawDepartment of Chemical and Systems Biology, ChEM-H and Stanford Cancer Institute, Stanford Medical School, Stanford University, Stanford, CA, 94305, USA.ORCID 0000-0003-4215-5206 Kwok-Kin WongLaura and Isaac Perlmutter Cancer Center, New York University Langone Health, New York, New York, 10016, USA.ORCID 0000-0001-6323-235X Nathanael S GrayDepartment of Chemical and Systems Biology, ChEM-H and Stanford Cancer Institute, Stanford Medical School, Stanford University, Stanford, CA, 94305, USA.ORCID 0000-0001-5354-7403 Funding
ATP-Dependent Chromatin Remodeling in Human MalignancyR01CA163915 · NCI · STANFORD UNIVERSITY · PI Gerald R. Crabtree · 2012 to 2026
$5.4MHIJACKING CANCER DRIVERS TO ACTIVATE PROAPOPTOTIC GENES IN DLBCLR01CA276167 · NCI · STANFORD UNIVERSITY · PI Gerald R. Crabtree, NATHANAEL Schiander GRAY · 2023 to 2026
$2.2MCombining CDK7 and MUC1-C inhibition to target different subtypes of small cell lung cancerR01CA282437 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI DONALD W. KUFE, Kwok Kin Wong · 2024 to 2026
$2.1MSmall molecule regulation of endogenous transcription factors for circuit-specific neuromodulationRF1MH126720 · NIMH · STANFORD UNIVERSITY · PI CRABTREE, GERALD R. · 2021 to 2021
$1.3M500 MHz NMR Spectrometer System with High Sensitivity Cryoprobe and Automated Sample Changer for Biochemical ResearchS10OD028697 · OD · STANFORD UNIVERSITY · PI BURNS, NOAH ZACHARY · 2020 to 2020
$709kSciex 6500+ QTrap Mass SpectrometerS10OD030332 · OD · SCRIPPS FLORIDA · PI CAMERON, MICHAEL DARIN · 2021 to 2021
$486kNCI NIH HHS R01 CA163915NCI NIH HHS R01 CA276167NCI NIH HHS R01 CA282437NIH HHS S10 OD028697NIH HHS S10 OD030332NIMH NIH HHS RF1 MH126720
6 · The paper itselfAbstract
Many chemotherapies are effective against cancers that display high levels of genome instability by disrupting or overwhelming the DNA damage response to induce cell death. PARP inhibitors (PARPi) exploit this vulnerability by stalling DNA repair particularly in homologous recombination (HR)-deficient cancer cells. Although PARPi are now used to treat BRCA1/2-mutated cancers such as ovarian and breast cancers, they are still limited to a narrow range of clinical indications and are susceptible to acquired resistance. Here, we introduce "DNA Damage Chemical Inducers of Proximity" (DD-CIPs), bivalent molecules that rewire the mechanism of action of conventional PARPi. The DD-CIPs function through chemical induced proximity between PARP1/2 and the chromatin remodeling protein, BRD4. From a candidate library of DD-CIPs, we identified DD-CIP1 which induces the DNA damage response (DDR) and apoptosis to a range of cancer lines at two-digit nanomolar concentrations. Further optimization yielded DD-CIP2, which induces tumor cell death at nanomolar concentrations across diverse blood and solid cancer cells, including cancer types that are insensitive to PARPi. Using small-cell lung cancer (SCLC) as a model, we found that DD-CIP2 triggers DDR, cell cycle arrest, and apoptosis
Identifiers
PMID41278667
PMCPMC12637661
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390